JNJ-77242113 治疗全身性脓疱型银屑病或红皮病型银屑病参与者的研究
一项评估 JNJ-77242113 治疗全身性脓疱型银屑病或红皮病型银屑病参与者的疗效和安全性的 3 期、多中心、开放标签研究
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Hokkaido、日本、060-0033
- JR Sapporo Hospital
-
Ichinomiya、日本、491-8558
- Ichinomiya Municipal Hospital
-
Kitakyushu-shi、日本、807-8556
- Hospital of the University of Occupational and Environmental Health
-
Kumamoto、日本、860-8556
- Kumamoto University Hospital
-
Nagoya、日本、467 8602
- Nagoya City University Hospital
-
Osaka、日本、550 0006
- Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital
-
Sendai、日本、980 8574
- Tohoku University Hospital
-
Shimotsuga Gun、日本、321 0293
- Dokkyo Medical University Hospital
-
Shinjuku、日本、160 0023
- Tokyo Medical University Hospital
-
Toyoake、日本、470-1192
- Fujita Health University Hospital
-
Tsu、日本、514 8507
- Mie University Hospital
-
tabashi City、日本、173 8606
- Teikyo University Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- The study participant has a diagnosis of generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP) at screening. For GPP, a diagnosis must be classified based on the criteria for diagnosis of GPP by the Japanese Dermatological Association (JDA); for EP, has a history of plaque-type psoriasis. In addition, has an involved body surface area (BSA) of lesion greater than or equal to (>=) 80 percent (%) at baseline
- Candidate for phototherapy or systemic treatment for psoriasis (either naive or history of previous treatment)
- A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) at screening and have a negative urine pregnancy test at Week 0 prior to administration of study intervention
- A male participant must agree not to plan to father a child while enrolled in this study or within 90 days after the last dose of study intervention
- A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose of study intervention
Exclusion Criteria:
- The study participant has a total score of JDA severity index for GPP >=14 at baseline if participants have a diagnosis of GPP
- The study participant has a differential diagnosis of the erythroderma (for example, erythroderma caused by lymphoma or drug eruption) other than EP
- The study participant has a history of or current diagnosis or signs or symptoms of severe, progressive, or uncontrolled liver, renal; cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- The study participant has a history of amyloidosis
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
- The study participant who doesn't meet the criteria of prior/current concomitant therapy and/or history/conditions of infections
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:JNJ-77242113- Participants With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP)
Participants with GPP or EP will receive JNJ-77242113 tablet orally. |
JNJ-77242113 tablet will be administered orally. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants With Generalized Pustular Psoriasis (GPP) Who Experienced Treatment Success at Week 16
大体时间:Week 16
|
Percentage of participants with GPP who experienced treatment success at Week 16 was reported. Treatment success for GPP was defined as at least "minimally improved" rating in Clinical Global Impression (CGI) scale for GPP based on Japanese Dermatological Association (JDA) total score. JDA severity index includes skin symptoms (area of erythema with pustules, total area of erythema, and area of edema; each scored 0-3) and systemic/laboratory findings (fever, white blood cell count, C-reactive protein, and serum albumin; each scored 0-2). JDA total score was sum of 2 assessments ranging from 0 (best) to 17 (worst). CGI ratings were defined as: 1=Very much improved (greater than or equal to [>=]3-point reduction in JDA total score), 2=Much improved (1-2-point reduction), 3=Minimally improved (no change in JDA total score, but >=20 percent (%) reduction in area of erythema with pustules or meaningful improvement in >=1 other parameter), 4=No change, 5=Worsened. Higher score = worsening. |
Week 16
|
|
Percentage of Participants With Erythrodermic Psoriasis (EP) Who Experience Treatment Success at Week 16
大体时间:Week 16
|
Percentage of participants with EP who experienced treatment success at Week 16 was reported. Treatment success for EP was defined as at least "minimally improved" rating in CGI scale for EP. The CGI scale is a clinician-rated 5-point scale with the following categories: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Worsened. Higher score indicated worsening. |
Week 16
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
根据JDA总分按CGI量表评估的GPP患者随时间推移实现治疗成功的百分比
大体时间:从基线(第 0 周)至第 156 周
|
从基线(第 0 周)至第 156 周
|
|
基于CGI量表随时间推移实现治疗成功的癫痫发作参与者百分比
大体时间:从基线(第 0 周)至第 156 周
|
从基线(第 0 周)至第 156 周
|
|
GPP日本皮肤病学会(JDA)严重程度指数总分随时间推移较基线的变化
大体时间:从基线(第 0 周)至第 156 周
|
从基线(第 0 周)至第 156 周
|
|
GPP的JDA严重程度指数分类随时间从基线的变化
大体时间:从基线(第 0 周)至第 156 周
|
从基线(第 0 周)至第 156 周
|
|
随时间推移的湿疹面积及严重程度指数(EASI)皮损累及体表面积(BSA)相对于基线的变化
大体时间:从基线(第0周)至第156周
|
从基线(第0周)至第156周
|
|
随时间推移达到研究者整体评估(IGA)分数为清除(0)或轻微(1)的参与者百分比
大体时间:基线(第0周)至第156周
|
基线(第0周)至第156周
|
|
随时间推移达到IGA评分清除(0)的参与者百分比
大体时间:基线(第 0 周)至第 156 周
|
基线(第 0 周)至第 156 周
|
|
随时间推移银屑病面积和严重程度指数(PASI)相对于基线的改善百分比
大体时间:从基线(第0周)至第156周
|
从基线(第0周)至第156周
|
|
随时间推移皮肤病生活质量指数(DLQI)评分相对于基线的变化
大体时间:从基线(第0周)至第156周
|
从基线(第0周)至第156周
|
|
随时间推移达到DLQI评分为0或1的参与者百分比
大体时间:基线(第0周)至第156周
|
基线(第0周)至第156周
|
|
随时间推移的基线变化:EuroQol-5维度5级(EQ-5D-5L)领域评分
大体时间:从基线(第 0 周)至第 156 周
|
从基线(第 0 周)至第 156 周
|
|
EQ-5D-5L视觉模拟量表(VAS)评分相对于基线的随时间变化
大体时间:从基线(第 0 周)至第 156 周
|
从基线(第 0 周)至第 156 周
|
|
出现治疗期间不良事件(TEAE)和治疗期间严重不良事件(TESAE)的参与者人数
大体时间:基线(第0周)至160周
|
基线(第0周)至160周
|
合作者和调查者
调查人员
- 研究主任:Janssen Pharmaceutical K.K., Japan Clinical Trial、Janssen Pharmaceutical K.K.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 77242113PSO3005
- 77242113PSO3005 (其他标识符:Janssen Research & Development, LLC)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.